Irreversible Electroporation and Nivolumab Combined with Intratumoral Administration of a Toll-Like Receptor Ligand, as a Means of In Vivo Vaccination for Metastatic Pancreatic Ductal Adenocarcinoma (PANFIRE-III). A Phase-I Study Protocol.
CpG-ODN
IMO-2125
PDAC
PET-C
ablation
checkpoint inhibition
immunotherapy
irreversible electroporation (IRE)
metastatic pancreatic cancer
nivolumab
toll-like receptor ligand
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
02 Aug 2021
02 Aug 2021
Historique:
received:
30
06
2021
revised:
24
07
2021
accepted:
28
07
2021
entrez:
7
8
2021
pubmed:
8
8
2021
medline:
8
8
2021
Statut:
epublish
Résumé
Irreversible electroporation (IRE) is a novel image-guided tumor ablation technique with the ability to generate a window for the establishment of systemic antitumor immunity. IRE transiently alters the tumor's immunosuppressive microenvironment while simultaneously generating antigen release, thereby instigating an adaptive immune response. Combining IRE with immunotherapeutic drugs, i.e., electroimmunotherapy, has synergistic potential and might induce a durable antitumor response. The primary objective of this study is to assess the safety of the combination of IRE with IMO-2125 (a toll-like receptor 9 ligand) and/or nivolumab in patients with metastatic pancreatic ductal adenocarcinoma (mPDAC). In this randomized controlled phase I clinical trial, 18 patients with mPDAC pretreated with chemotherapy will be enrolled in one of three study arms: A (control): nivolumab monotherapy; B: percutaneous IRE of the primary tumor followed by nivolumab; or C: intratumoral injection of IMO-2125 followed by percutaneous IRE of the primary tumor and nivolumab. Assessments include contrast enhanced computed tomography (ceCT),
Identifiants
pubmed: 34359801
pii: cancers13153902
doi: 10.3390/cancers13153902
pmc: PMC8345515
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : Adessium Foundation
ID : CCA2019-5-56
Organisme : Cancer Center Amsterdam
ID : CCA2018-5-44
Références
Ann Oncol. 2018 Nov 1;29(11):2163-2174
pubmed: 30295695
Clin Cancer Res. 2006 Sep 15;12(18):5423-34
pubmed: 17000676
Int J Hyperthermia. 2019;36(1):130-138
pubmed: 30676126
BMC Cancer. 2014 Jul 26;14:540
pubmed: 25064086
Pancreatology. 2020 Apr;20(3):477-484
pubmed: 32131993
N Engl J Med. 2011 May 12;364(19):1817-25
pubmed: 21561347
JCI Insight. 2017 Mar 23;2(6):e90521
pubmed: 28352658
Can Assoc Radiol J. 2018 Feb;69(1):38-50
pubmed: 29458954
Med Oncol. 2017 Mar;34(3):38
pubmed: 28161827
Radiology. 2020 May;295(2):254-272
pubmed: 32208094
Ann Surg Oncol. 2019 Mar;26(3):800-806
pubmed: 30610562
Oncol Rev. 2019 Aug 01;13(2):430
pubmed: 31456872
Cancer Treat Rev. 2020 Jun;86:102016
pubmed: 32247999
Nucleic Acid Ther. 2012 Apr;22(2):77-89
pubmed: 22352814
Cell Death Differ. 2016 Jun;23(6):938-51
pubmed: 26891691
J Vasc Interv Radiol. 2020 Oct;31(10):1600-1608
pubmed: 32861569
Gan To Kagaku Ryoho. 2009 Dec;36(13):2495-501
pubmed: 20009446
J Nucl Med. 2020 Oct;61(10):1455-1460
pubmed: 32060213
Br J Radiol. 1953 May;26(305):234-41
pubmed: 13042090
Cancer Immunol Immunother. 2011 Oct;60(10):1419-30
pubmed: 21644036
J Exp Med. 2011 Sep 26;208(10):2005-16
pubmed: 21930765
J Gastrointest Oncol. 2018 Apr;9(2):275-281
pubmed: 29755766
Ann Surg Oncol. 2016 Dec;23(13):4352-4360
pubmed: 27370653
Immunity. 2013 Jul 25;39(1):74-88
pubmed: 23890065
Anticancer Res. 2014 Jan;34(1):289-93
pubmed: 24403476
BMJ Open. 2017 Sep 1;7(9):e015810
pubmed: 28864693
Br J Cancer. 2006 Oct 9;95(7):896-905
pubmed: 16953240
Theranostics. 2020 Jan 1;10(2):925-937
pubmed: 31903160
Nat Commun. 2018 Nov 7;9(1):4664
pubmed: 30405135
Radiology. 2020 Jan;294(1):212-220
pubmed: 31687922
Surgery. 2020 Oct;168(4):610-616
pubmed: 32631655
Nat Rev Immunol. 2015 Jul;15(7):405-14
pubmed: 26027717
J Nucl Med. 2009 May;50 Suppl 1:122S-50S
pubmed: 19403881
Clin Cancer Res. 2008 Jul 15;14(14):4532-42
pubmed: 18628468
J Vasc Interv Radiol. 2018 Dec;29(12):1764-1769
pubmed: 30316676
Oncoimmunology. 2019 Aug 28;8(11):1652532
pubmed: 31646081
Immunity. 2013 Jul 25;39(1):38-48
pubmed: 23890062
CA Cancer J Clin. 2017 May 6;67(3):177-193
pubmed: 28248415
Ann Surg. 2011 Feb;253(2):328-35
pubmed: 21217520
Trials. 2020 Apr 16;21(1):334
pubmed: 32299515
Cancer Sci. 2004 Jul;95(7):583-7
pubmed: 15245594
Oncotarget. 2017 Oct 19;8(60):101795-101807
pubmed: 29254205
Br J Cancer. 2017 Jun 27;117(1):33-40
pubmed: 28588322
Chin Clin Oncol. 2019 Dec;8(6):61
pubmed: 31865711
Nat Rev Clin Oncol. 2016 Mar;13(3):143-58
pubmed: 26598942
Trends Immunol. 2013 Feb;34(2):67-73
pubmed: 23122052
Technol Cancer Res Treat. 2007 Feb;6(1):37-48
pubmed: 17241099
J Clin Oncol. 2013 Jul 1;31(19):2388-95
pubmed: 23715562
Ann Surg Oncol. 2016 May;23(5):1736-43
pubmed: 26714959
Radiology. 2017 Feb;282(2):585-597
pubmed: 27604035
Clin Cancer Res. 2010 Mar 15;16(6):1726-36
pubmed: 20215542
Lancet Oncol. 2017 Mar;18(3):e143-e152
pubmed: 28271869
Cancer Lett. 2012 Apr 1;317(1):16-23
pubmed: 22079741
Ann Biomed Eng. 2020 May;48(5):1451-1462
pubmed: 32026232
Cardiovasc Intervent Radiol. 2014 Dec;37(6):1523-9
pubmed: 25212418
Dig Surg. 2015;32(2):90-7
pubmed: 25765775
Science. 2015 Apr 3;348(6230):69-74
pubmed: 25838375
Lancet Oncol. 2016 Jun;17(6):801-810
pubmed: 27160474
Lancet. 2011 Aug 13;378(9791):607-20
pubmed: 21620466
Ann Surg. 2015 Sep;262(3):486-94; discussion 492-4
pubmed: 26258317
Tech Vasc Interv Radiol. 2020 Jun;23(2):100675
pubmed: 32591191
Mol Cancer Ther. 2008 Feb;7(2):286-96
pubmed: 18281514
Radiology. 2019 Jul;292(1):25-34
pubmed: 31012818
Cancers (Basel). 2018 Jan 10;10(1):
pubmed: 29320420
Front Oncol. 2020 Jul 28;10:1235
pubmed: 32850371
Clin Cancer Res. 2007 May 15;13(10):2961-9
pubmed: 17504997
Eur J Nucl Med Mol Imaging. 2010 Jan;37(1):181-200
pubmed: 19915839
Transl Oncol. 2020 Dec;13(12):100856
pubmed: 32862105
Oncol Lett. 2015 Apr;9(4):1549-1556
pubmed: 25788999
Nat Commun. 2019 Feb 22;10(1):899
pubmed: 30796212
Cancer Treat Rev. 2014 May;40(4):513-22
pubmed: 24315741
Trends Immunol. 2015 Apr;36(4):250-6
pubmed: 25758021
Eur J Radiol. 2018 Sep;106:128-136
pubmed: 30150034
Front Immunol. 2021 Apr 14;12:617365
pubmed: 33936033